Medicenna Therapeutics Quote - MDNA

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.10

Bid

1.09

Offer

1.15

Volume

10,411

1.09 Day's Range 1.15

0.89 52 Week Range 2.98

Market Cap

76.601M

Previous Close

1.09

Open

1.15

Last Trade

100

1.1

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

72,743

Shares Outstanding

69,637,000

Dividend Yield

PE Ratio

-3.01

Earnings Per Share (EPS)

-0.37

Revenue

Net Profit

-25.47M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.medicenna.com

Headquarters

Toronto, Ontario, Can

Founded

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.09. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.89 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $75.90 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -3.01.

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and...

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD...

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.11	11.1111111111	0.99	1.15	0.97	55122	1.05453716	CS
4	-0.29	-20.8633093525	1.39	1.39	0.89	72725	1.08377016	CS
12	-0.58	-34.5238095238	1.68	1.98	0.89	72743	1.29668255	CS
26	-0.99	-47.3684210526	2.09	2.62	0.89	76671	1.68440387	CS
52	-0.35	-24.1379310345	1.45	2.98	0.89	98313	1.91078103	CS
156	-0.59	-34.9112426036	1.69	2.98	0.215	65517	1.39362218	CS
260	-1.81	-62.1993127148	2.91	7.25	0.215	69120	2.6461942	CS

MDNA - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics share price?

The current share price of Medicenna Therapeutics is $ 1.10

How many Medicenna Therapeutics shares are in issue?

Medicenna Therapeutics has 69,637,000 shares in issue

What is the market cap of Medicenna Therapeutics?

The market capitalisation of Medicenna Therapeutics is CAD 75.9M

What is the 1 year trading range for Medicenna Therapeutics share price?

Medicenna Therapeutics has traded in the range of $ 0.89 to $ 2.98 during the past year

What is the PE ratio of Medicenna Therapeutics?

The price to earnings ratio of Medicenna Therapeutics is -3.01

What is the reporting currency for Medicenna Therapeutics?

Medicenna Therapeutics reports financial results in CAD

What is the latest annual profit for Medicenna Therapeutics?

The latest annual profit of Medicenna Therapeutics is CAD -25.47M

What is the registered address of Medicenna Therapeutics?

The registered address for Medicenna Therapeutics is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2

What is the Medicenna Therapeutics website address?

The website address for Medicenna Therapeutics is www.medicenna.com

Which industry sector does Medicenna Therapeutics operate in?

Medicenna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BNGBengal Energy Ltd	$ 0.015 (50.00%)	17k
AUMNGolden Minerals Company	$ 0.265 (32.50%)	117.38k
RTGRTG Mining Inc	$ 0.025 (25.00%)	28k
NFINFI Group Inc	$ 13.41 (20.70%)	18.36k
FLNTFlint Corporation	$ 0.03 (20.00%)	8.27k
GMTNGold Mountain Mining Corp	$ 0.015 (-25.00%)	44.9k
ESMEuro Sun Mining Inc	$ 0.05 (-16.67%)	1.29M
APLIAppili Therapeutics Inc	$ 0.03 (-14.29%)	9k
PPRPrairie Provident Resources Inc	$ 0.035 (-12.50%)	427.9k
EVTEconomic Investment Trust Limited	$ 161.22 (-12.38%)	521
CNQCanadian Natural Resources Ltd	$ 42.23 (2.03%)	10.39M
SUSuncor Energy Inc	$ 52.66 (1.82%)	7.9M
MFCManulife Financial Corporation	$ 42.32 (3.22%)	7.87M
PPLPembina Pipeline Corporation	$ 55.96 (0.68%)	7.78M
CVECenovus Energy Inc	$ 19.39 (2.86%)	7.73M

cjstocksup 2 minutes ago

Newsweek journalist defends Trump’s tariffs & leaves Bill Maher almost speechless

@bungarsargon
explains how in the 70s, the middle class had power & wealth

But then “free trade” shipped those jobs overseas to China which pays slave wages

Tariffs

cjstocksup 3 minutes ago

New pic just dropped of the reporter who hit Trump in the face with the boom mic
https://x.com/DC_Draino/status/1900972016548606009

improving 3 minutes ago

Tough to know LC and Investor 82 could be reassigned.

NWBO

janice shell 4 minutes ago

Coincidentally, I've been watching CNN, and they just did a longish interview with a British economist. She said Bessent and others have for some time--since before he hooked up with Trump--wanted to bring about a complete reorientation of the U.S. economy. That they believe the debt needs to be dea

cjstocksup 4 minutes ago

🚨 Statement from
@POTUS
https://x.com/RapidResponse47/status/1900978458760515769

cjstocksup 5 minutes ago

@DC_Draino
Do these Leftist Tesla vandals not realize that the car has more security cameras than a 7/11?

They’re all going to be caught
https://x.com/DC_Draino/status/1901027009800626403

mister 6 minutes ago

I had a chance to go back and listen and read Lebby's interviews and relistened to Yves last call. My opinion is that all of you non-believers or paid shorts who seem to get so much enjoyment out of seeing long term shareholders lose money definitely deserve a place in hell. Telling people they shou

LWLG

cjstocksup 8 minutes ago

Absolutely insane that almost every other Trump Executive Order gets a national injunction

But we had to endure 2 full years of Biden’s vaccine mandates, masks on kids, no religious exemptions, priests and hairdressers getting arrested, nurses, soldiers, and firefighters being fired,

OMOLIVES 8 minutes ago

I extracted the last part to drive it home. That being that all this talk is merely posturing. And Canadian politicians are just as damn funny as US politicians...slimy too...lol. Given such means that the King of England through the power of the Governor General and Monarchy could just veto any

RIOgrande44 10 minutes ago

The PBM's are stealing all the profits. Those bollies are getting sexy.

NextPlat is a global e-commerce platform company...... Its got to be about time for a web 3 and an ecommerce platform update!!! This appears to be their main focus.

PBM

arizona1 10 minutes ago

Inflated market valuations from inflationary government spending during the Biden years has been a huge factor.

Quit using big words you don't understand captain Conix.

learningcurve2020 10 minutes ago

Caught in another lie since you have multiple postings every month.

NWBO

igotthemojo 10 minutes ago

Seriously?…lol…Trump doesn’t want Canada as a state and he knows that will never happen…what he wants is for them to know that the US can and will exert their dominance…when he tells them to do more to ensure that fentanyl does not cross their border into the U.S., he expects them to do whatever it

FCEL

facts_matter14 12 minutes ago

Is it really a “product” when it’s only used as a prop in a YouTube video, never actually being produced for sale???????

It’s so funny to see the BSR Queen posting videos from over a year ago, of 2 props, saying they are “coming soon”.

Yeah, they were real and legitim

SRMX

fuagf 13 minutes ago

It's fact we all know, still --- Who is to Blame for Gas Prices and Inflation

American families have been feeling the economic squeeze. Prices are up, and a trip to the grocery store or the gas pump can lead to hard choices. But we need to be clear about one of the main drivers of inf

Morita702 13 minutes ago

Can you image the old mustaches sitting in a bar somewhere in Jersey with a legal pad trying to put this press release together. Things crossed out, misspelled words, broken pencils. It is comedy. Then the dreaming takes over. This one is gonna be the one! We are gonna do it! Get it all teed up, pa

AHRO

arizona1 13 minutes ago

Art Candee 🍿🥤
@artcandee.bsky.social
Surely MAGA folks are screeching that they should have raked the forests in Oklahoma and Texas because of the wildfires, right?

Right?

B402 14 minutes ago

Oh boy you got em, lol......Although it wouldn't have been a bit surprising ;)

Instead of playing games perhaps you should have read the IGs memorandum on USaid, Even the UN won't account for what they do with the money.........Being accountable with billions of dollars was big proble

Top Penny 15 minutes ago

Could be real

PSRU

bigfart 15 minutes ago

Elon musk sunk this one him and Trump should probably be in jail

TSLA

SmoothTrader61 17 minutes ago

Number 5 on breakout boards if that actually matters

GDVM

janice shell 18 minutes ago

Yes. See how Tommy Tuberville likes THAT!

jay_tee 18 minutes ago

You forgot $INQR also!!! Yayyy!

INQR

janice shell 19 minutes ago

LOLOLOLOLOL!!

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Medicenna Therapeutics Corp (MDNA) Share Price

Medicenna Therapeutics Corp (MDNA)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Medicenna Therapeutics Corp

Ask ADVFN Intelligence (AI)

MDNA Latest News

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

MDNA - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free